| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d6c045c3c6f0c077c4a41eb22aedb45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eea866b171d77ebffca55670e5b6c98b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_831d67cea5c33ccf93afaa82894f34b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_082ab1b556b37dc482d43ae14425ef5d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2009-08-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7233baf2241ae734f79e3873ee14b795
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f416df8e1f1f3096de4654e52f99be8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6abe8d1fd31b549c0cd98c3e2750d409 |
| publicationDate |
2010-03-04^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010025410-A2 |
| titleOfInvention |
Screening method for identifying patients at risk of adverse hepatologic events |
| abstract |
This present invention provides methods and kits for identifying patients at risk of suffering from a drug induced liver injury, particularly for an antioxidant drug, or for identifying patients who are suffering from early stages of a liver disorder by assessing the levels of apolipoprotein in a sample of the patient and comparing that to a reference value. The reference value is predetermined by identifying a population sample and determining an upper limit of normal value. This value is then used as a reference point for comparison of apolipoprotein levels from patient samples. In one embodiment, apolipoprotein levels are combined with ATL and/or total bilirubin levels for predicting liver damage, hepatotoxicity or hepatic events after drug administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3373012-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012122024-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012122024-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012092430-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018162502-A1 |
| priorityDate |
2008-08-28^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |